Financials Arvinas, Inc.

Equities

ARVN

US04335A1051

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
32.37 USD +2.44% Intraday chart for Arvinas, Inc. -6.77% -21.36%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,574 4,090 4,343 1,821 2,799 2,211 - -
Enterprise Value (EV) 1 1,567 3,505 4,237 611.1 1,539 1,398 1,767 1,835
P/E ratio -19.3 x -28.1 x -21.5 x -6.44 x -6.22 x -6.13 x -6.19 x -7.08 x
Yield - - - - - - - -
Capitalization / Revenue 36.6 x 188 x 93 x 13.9 x 35.7 x 13.8 x 10.2 x 7.6 x
EV / Revenue 36.5 x 161 x 90.7 x 4.65 x 19.6 x 8.7 x 8.14 x 6.3 x
EV / EBITDA -31.4 x -28.8 x -22.2 x -2.38 x -3.88 x -3.45 x -4.97 x -5.24 x
EV / FCF -33.4 x -36.4 x 7.64 x -2.18 x -4.39 x -5.29 x -5.35 x -5.85 x
FCF Yield -2.99% -2.75% 13.1% -45.9% -22.8% -18.9% -18.7% -17.1%
Price to Book - - 5.57 x 3.22 x 3.46 x 8.78 x -30.9 x 114 x
Nbr of stocks (in thousands) 38,304 48,158 52,872 53,228 67,999 68,308 - -
Reference price 2 41.09 84.93 82.14 34.21 41.16 32.37 32.37 32.37
Announcement Date 3/16/20 3/1/21 2/28/22 2/23/23 2/27/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 42.98 21.8 46.7 131.4 78.5 160.6 216.9 291.1
EBITDA 1 -49.96 -121.7 -190.5 -256.9 -396.7 -405 -355.2 -350.2
EBIT 1 -51.52 -124.9 -195.3 -263.2 -401.5 -378.2 -368.1 -344.3
Operating Margin -119.89% -572.69% -418.2% -200.3% -511.46% -235.5% -169.69% -118.27%
Earnings before Tax (EBT) 1 -70.29 -119.3 -191 -261.6 -363.9 -345.6 -354.8 -333.8
Net income 1 -70.29 -119.3 -191 -282.5 -367.3 -327.3 -336.2 -318.7
Net margin -163.56% -547.35% -408.99% -214.99% -467.9% -203.82% -154.97% -109.48%
EPS 2 -2.130 -3.020 -3.820 -5.310 -6.620 -5.284 -5.228 -4.570
Free Cash Flow 1 -46.87 -96.2 554.7 -280.3 -350.7 -264.2 -330.3 -313.8
FCF margin -109.06% -441.27% 1,187.79% -213.32% -446.75% -164.53% -152.28% -107.8%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 3/16/20 3/1/21 2/28/22 2/23/23 2/27/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 9.285 26.3 24.2 31.3 30.3 38 32.5 54.5 34.6 -43.1 34.85 56.13 34.19 40.62 28.11
EBITDA 1 -46.13 - - - - - - - - -164.1 -61.87 -62.94 -64.01 - -
EBIT 1 -47.33 -54.4 -60 -68.3 -67.2 -75.4 -87.7 -74.6 -73.9 -165.3 -97.86 -90.9 -104.6 -92.59 -136.3
Operating Margin -509.77% -206.84% -247.93% -218.21% -221.78% -198.42% -269.85% -136.88% -213.58% 383.53% -280.82% -161.94% -305.95% -227.96% -484.81%
Earnings before Tax (EBT) 1 -46.75 -53 -58.9 -66.6 -64 -72.1 -81.2 -65.6 -63.9 -153.2 -89.13 -77.29 -94.65 -101.1 -125.5
Net income 1 -46.75 -53 -63.4 -70 -66.2 -82.9 -81.9 -66.6 -64 -154.8 -91.09 -71.53 -97.41 -77.33 -125.5
Net margin -503.53% -201.52% -261.98% -223.64% -218.48% -218.16% -252% -122.2% -184.97% 359.16% -261.41% -127.43% -284.9% -190.4% -446.52%
EPS 2 -0.9400 -1.000 -1.200 -1.320 -1.240 -1.560 -1.540 -1.250 -1.180 -2.530 -1.350 -0.9732 -1.441 -1.399 -1.593
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 11/3/21 2/28/22 5/5/22 8/4/22 11/8/22 2/23/23 5/5/23 8/8/23 11/7/23 2/27/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 7.21 585 106 1,210 1,260 814 444 376
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -46.9 -96.2 555 -280 -351 -264 -330 -314
ROE (net income / shareholders' equity) - - -26.8% -42% -60% -85.2% -49% -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 - - 14.70 10.60 11.90 3.690 -1.050 0.2800
Cash Flow per Share 2 - - 11.20 -5.140 -6.270 0.5200 0.6200 -
Capex 1 6.24 6.45 4.7 6.8 2.9 8.62 12.9 18.2
Capex / Sales 14.53% 29.57% 10.06% 5.18% 3.69% 5.37% 5.93% 6.25%
Announcement Date 3/16/20 3/1/21 2/28/22 2/23/23 2/27/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
32.37 USD
Average target price
70.83 USD
Spread / Average Target
+118.82%
Consensus
  1. Stock Market
  2. Equities
  3. ARVN Stock
  4. Financials Arvinas, Inc.